Role of nanotechnology behind the success of mRNA vaccines for COVID-19

Ioannis P. Trougakos, Evangelos Terpos, Harry Alexopoulos, Marianna Politou, Dimitrios Paraskevis, Andreas Scorilas, Efstathios Kastritis, Evangelos Andreakos, Meletios A Dimopoulos

Article2021

Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database

Min Seo Kim, Se Yong Jung, Jong Gyun Ahn, Se-Jin Park, Yehuda Shoenfeld, Andreas Kronbichler, Ai Koyanagi, Elena Dragioti, Kalthoum Tizaoui, Sung Hwi Hong, Louis Jacob, Joe‐Elie Salem, Dong Keon Yon, Seung Won Lee, Shuji Ogino, Hanna Kim, Jerome H. Kim, Jean‐Louis Excler, Florian Marks, J. D. Clemens, Michael Eisenhut, Yvonne Barnett, Laurie T. Butler, Cristian Ilie, Eui‐Cheol Shin, Jae Il Shin, Lee Smith

Letter2021

Why two doses of the BNT162b2 mRNA COVID-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA COVID-19 and other vaccines

Carlo La Vecchia, Stefano Centanni, Alberto Giovanni Gerli

Article2026

Tu1647 HUMORAL IMMUNOGENICITY TO MRNA COVID-19 VACCINES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH OZANIMOD

Freddy Caldera, Aditi Basu Bal, Ruifeng Hu, John Schwarz, Yi Luo, Jiangwei Zhang, Sarah Harris

Article2026

Tu1647 HUMORAL IMMUNOGENICITY TO MRNA COVID-19 VACCINES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH OZANIMOD

Freddy Caldera, Aditi Basu Bal, Ruifeng Hu, John Schwarz, Yi Luo, Jiangwei Zhang, Sarah Harris